Semaglutide
The most widely prescribed weight loss medication in the world, sold as Wegovy and Ozempic. Works by dramatically reducing appetite and food cravings — most people report feeling full much faster and losing interest in snacking. In clinical trials, patients lost an average of 15-17% of their body weight. Also available as a daily pill (Rybelsus). Originally developed for type 2 diabetes, it also helps control blood sugar levels.
Semaglutide is a GLP-1 receptor agonist that has fundamentally changed the treatment of obesity and type 2 diabetes. Originally developed by Novo Nordisk, it is available as a once-weekly subcutaneous injection (Ozempic for diabetes, Wegovy for weight loss) and a once-daily oral tablet (Rybelsus). In landmark clinical trials, patients on the 2.4 mg weekly dose lost an average of 15-17% of their body weight over 68 weeks — results that were previously only achievable through bariatric surgery.
Semaglutide works by mimicking the natural incretin hormone GLP-1, which is released after eating. It reduces appetite by acting on hunger centers in the brain, slows gastric emptying to increase feelings of fullness, and enhances insulin secretion to improve blood sugar control. The molecule has been engineered with a fatty acid side chain that allows it to bind to albumin in the blood, dramatically extending its half-life from minutes to approximately one week.
Beyond weight loss and diabetes, semaglutide is being studied for cardiovascular protection, non-alcoholic fatty liver disease (NAFLD), and even neurodegenerative conditions. The SELECT trial demonstrated a 20% reduction in major cardiovascular events in overweight patients. It is one of the most extensively studied peptide medications in history, with a safety profile documented across tens of thousands of patients in clinical trials.
Dosage
2.4 mg subcutaneous once weekly (Wegovy maintenance dose)
Dosages shown are for research reference only. Always consult a qualified healthcare provider.
Administration
Subcutaneous injection (weekly). Oral formulation available (Rybelsus).
Get Research-Grade Semaglutide
99%+ purity · US-based · third-party lab tested
Getting Started — Here's What You'll Need
Effects
Weight Loss
Average 15-17% body weight reduction in clinical trials, one of the most effective anti-obesity medications available.
Appetite Suppression
Dramatically reduces hunger and food cravings by acting on hypothalamic appetite centers.
Blood Sugar Control
Glucose-dependent insulin secretion provides strong glycemic control with low hypoglycemia risk.
Gastric Emptying
Slows stomach emptying, prolonging satiety after meals and reducing portion sizes.
Cardiovascular Benefit
SELECT trial showed reduced cardiovascular events in patients with obesity.
Mechanism of Action
Semaglutide is a modified version of the natural incretin hormone GLP-1, engineered with 94% structural homology to the native peptide. It binds to GLP-1 receptors expressed throughout the body, triggering a cascade of metabolic effects. In the pancreas, it stimulates glucose-dependent insulin secretion from beta cells while suppressing glucagon release from alpha cells, providing dual glycemic control that only activates when blood sugar is elevated.
In the central nervous system, semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamic arcuate nucleus and the brainstem's nucleus tractus solitarius. This suppresses appetite by modulating POMC/CART (anorexigenic) and NPY/AgRP (orexigenic) neuronal pathways. The result is a significant reduction in hunger, food cravings, and caloric intake — patients typically experience a fundamental shift in their relationship with food.
The extended duration of action comes from a C18 fatty di-acid chain attached at position 26 (lysine), which enables strong non-covalent binding to circulating albumin. This albumin binding shields semaglutide from DPP-4 enzymatic degradation — the process that destroys native GLP-1 within minutes — extending its half-life to approximately 7 days. Additionally, semaglutide slows gastric emptying through vagal nerve signaling, contributing to post-meal satiety and reduced glycemic excursions.
Regulatory Status
FDA approved. Ozempic (2017), Wegovy (2021), Rybelsus (2019). Novo Nordisk.
Risks & Safety
Common
nausea (30-45% of users), vomiting, diarrhea, constipation, stomach pain, headache.
Serious
inflammation of the pancreas (pancreatitis), gallstones, kidney problems from dehydration, loss of muscle mass alongside fat.
Rare
thyroid tumours seen in animal studies, severe allergic reactions.
Compare Semaglutide With
Research Papers
30Published: February 11, 2026
AI Summary
GLP-1 RAs may be linked to new-onset optic nerve damage (NAION) in veterans with diabetes. The finding warrants further study as use of these drugs grows.
Published: February 11, 2026
AI Summary
The Sim-Q questionnaire was validated for measuring treatment simplicity in type 2 diabetes. It may help assess how easy or complex diabetes regimens are for patients.
Published: February 11, 2026
AI Summary
Kuwaiti experts recommended a multidisciplinary CKM care model with broader use of GLP-1 RAs like semaglutide. The approach could reduce disease burden in high-risk populations.
Published: February 11, 2026
AI Summary
Breast cancer survivors on GLP-1 RAs had modest weight loss and better overall survival than matched controls. The drugs did not affect disease-free survival.
Published: January 26, 2025
AI Summary
The study evaluated the clinical and economic impact of semaglutide in type 2 diabetes patients at a Saudi Arabian tertiary hospital.
Published: February 8, 2026
AI Summary
The oral semaglutide enhancer SNAC altered gut microbes, lowered butyrate, and raised inflammation in rats. The findings suggest a need for delivery methods that may be gentler on the microbiome.
Published: February 9, 2026
AI Summary
Exercise improved gut adaptation and sensitivity to gut peptides in male mice. The work may explain how physical activity helps regulate appetite and weight.
Published: February 10, 2026
AI Summary
Semaglutide limited loss of lean mass and drop in energy expenditure seen with diet restriction in obese minipigs. The drug may help preserve metabolism during weight loss.
Published: January 9, 2026
AI Summary
Semaglutide improved acne, hidradenitis suppurativa, and sebum production over 24 months. The improvements were tied to metabolic changes (BMI, HbA1c, glucose, insulin).
Published: February 18, 2026
AI Summary
A meta-analysis evaluated the link between GLP-1 RAs and colon cancer risk in adults with type 2 diabetes or obesity.
Published: February 8, 2026
AI Summary
The study analyzed trends and profiles of semaglutide prescriptions by general practitioners in New South Wales from 2020 to 2023.
Published: February 24, 2026
AI Summary
The study evaluated semaglutide's effect on BMI and cardiometabolic markers in adolescents with obesity and monogenic obesity-related gene variants.
Published: February 8, 2026
AI Summary
Semaglutide slowed osteoarthritis in obese mice by shifting chondrocyte metabolism from glycolysis to oxidative phosphorylation via the GLP-1R-AMPK-PFKFB3 axis. The effect was independent of weight loss.
Published: February 1, 2026
AI Summary
A patient developed pleural and pericardial effusions likely linked to semaglutide. The case highlights the need to watch for new adverse effects as use expands.
Published: February 9, 2026
AI Summary
Abstract too short to summarize.
Published: February 1, 2026
AI Summary
Abstract too short to summarize.
Published: February 1, 2026
AI Summary
Abstract too short to summarize.
Published: February 8, 2026
AI Summary
Abstract too short to summarize.
Published: February 8, 2026
AI Summary
Abstract too short to summarize.
Published: January 6, 2026
AI Summary
A patient developed a pustular rash after a semaglutide dose increase, likely related to the excipient propylene glycol rather than the active drug. The case suggests checking ingredient lists when investigating new reactions.
Published: February 8, 2026
AI Summary
Semaglutide showed possible neuroprotective effects on the left temporal lobe in overweight adults over 24 weeks. Brain imaging suggested benefits for structure and function.
Published: February 6, 2026
AI Summary
The study evaluated the effect of semaglutide and tirzepatide on bone in patients at higher fracture risk.
Published: February 4, 2026
AI Summary
A case report and literature review examined semaglutide use in early pregnancy and pregnancy outcomes. Data on safety in pregnancy remain limited.
Published: February 4, 2026
AI Summary
GLP-1 RAs were linked to better outcomes for arteriovenous fistulae in dialysis patients. The drugs may help preserve vascular access.
Published: February 4, 2026
AI Summary
Adding hepatic GLP-1R agonism to GLP-1 analogs boosted weight loss by increasing energy expenditure. The approach may avoid cardiovascular risks from glucagon receptor agonism.
Published: February 4, 2026
AI Summary
Oral semaglutide improved quality of life and metabolic parameters in type 2 diabetes patients in a multicenter observational study.
Published: February 3, 2026
AI Summary
Updated Medicare spending estimates suggest semaglutide could save Medicare hundreds of millions to billions over 10 years under new pricing. Savings depend on uptake and generic entry.
Published: February 2, 2026
AI Summary
A PET/CT scan showed multi-organ effects from a single semaglutide dose, including gastroparesis, cholecystitis, and colitis. The case highlights the need to recognize GLP-1-related imaging findings.
Published: January 4, 2026
AI Summary
A teenager developed deep vein thrombosis within two weeks of starting oral semaglutide. The case suggests a possible link and emphasizes the need for supervision during off-label use.
Published: June 3, 2025
AI Summary
Duodenal electroporation plus GLP-1 RA allowed most type 2 diabetes patients to stop insulin. At 24 months, efficacy and safety were sustained.
Frequently Asked Questions
What is Semaglutide?
The most widely prescribed weight loss medication in the world, sold as Wegovy and Ozempic. Works by dramatically reducing appetite and food cravings — most people report feeling full much faster and losing interest in snacking. In clinical trials, patients lost an average of 15-17% of their body weight. Also available as a daily pill (Rybelsus). Originally developed for type 2 diabetes, it also helps control blood sugar levels.
What is Semaglutide used for?
The most widely prescribed weight loss medication in the world, sold as Wegovy and Ozempic. Works by dramatically reducing appetite and food cravings — most people report feeling full much faster and losing interest in snacking. In clinical trials, patients lost an average of 15-17% of their body weight. Also available as a daily pill (Rybelsus). Originally developed for type 2 diabetes, it also helps control blood sugar levels.
What is the dosage for Semaglutide?
Weight management (Wegovy): 0.25 mg subcutaneous once weekly, escalating over 16 weeks to 2.4 mg once weekly. Diabetes (Ozempic): 0.25 mg subcutaneous once weekly, escalating to 1-2 mg once weekly. Oral (Rybelsus): 3 mg once daily for 30 days, then 7-14 mg once daily on an empty stomach.
What are the side effects of Semaglutide?
Common: nausea (30-45% of users), vomiting, diarrhea, constipation, stomach pain, headache. Serious: inflammation of the pancreas (pancreatitis), gallstones, kidney problems from dehydration, loss of muscle mass alongside fat. Rare: thyroid tumours seen in animal studies, severe allergic reactions.
How does Semaglutide work?
Semaglutide is a modified version of the natural incretin hormone GLP-1, engineered with 94% structural homology to the native peptide. It binds to GLP-1 receptors expressed throughout the body, triggering a cascade of metabolic effects. In the pancreas, it stimulates glucose-dependent insulin secretion from beta cells while suppressing glucagon release from alpha cells, providing dual glycemic control that only activates when blood sugar is elevated. In the central nervous system, semaglutide crosses the blood-brain barrier and acts on GLP-1 receptors in the hypothalamic arcuate nucleus and the brainstem's nucleus tractus solitarius. This suppresses appetite by modulating POMC/CART (anorexigenic) and NPY/AgRP (orexigenic) neuronal pathways. The result is a significant reduction in hunger, food cravings, and caloric intake — patients typically experience a fundamental shift in their relationship with food. The extended duration of action comes from a C18 fatty di-acid chain attached at position 26 (lysine), which enables strong non-covalent binding to circulating albumin. This albumin binding shields semaglutide from DPP-4 enzymatic degradation — the process that destroys native GLP-1 within minutes — extending its half-life to approximately 7 days. Additionally, semaglutide slows gastric emptying through vagal nerve signaling, contributing to post-meal satiety and reduced glycemic excursions.
How is Semaglutide administered?
Semaglutide is administered via subcutaneous injection (weekly). oral formulation available (rybelsus)..
What is the half-life of Semaglutide?
The half-life of Semaglutide is 168 hours (7 days).
Is Semaglutide legal?
FDA approved. Ozempic (2017), Wegovy (2021), Rybelsus (2019). Novo Nordisk.
Related Peptides
5-Amino-1MQ
A pill that aims to switch fat cells from 'storage mode' to 'burning mode' by blocking an enzyme (NNMT) that is overactive in the fat tissue of overweight people. Not technically a peptide, but commonly sold alongside them. Unlike appetite suppressants, this targets the fat cells directly rather than making you eat less. The science is promising in lab studies, but there are no completed human trials yet.
Adipotide
An extreme experimental approach to fat loss — it physically destroys the blood vessels that feed fat tissue, starving fat cells until they die. Originally developed using anti-cancer technology at MD Anderson Cancer Center. While it did reduce fat in monkey studies, it also caused serious kidney damage, which has effectively stopped its development. Not available for human use.
AOD-9604
A small piece of human growth hormone (amino acids 176-191) designed to keep only the fat-burning effects while removing the unwanted side effects of full growth hormone (like swelling and blood sugar problems). The idea is promising — burn fat without the downsides — but it failed to show significant weight loss in clinical trials. Still widely used in research and wellness clinics despite the weak clinical evidence.
Cagrilintide
A long-acting version of amylin, a natural hormone your body releases after eating that tells your brain you're full. It works through a completely different pathway than GLP-1 drugs like semaglutide, which is why combining them (as CagriSema) produces even better results. On its own, it reduces how much you eat per meal by signalling fullness earlier. Developed by Novo Nordisk, mainly as part of the CagriSema combination.